Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline solution for injection Clear all
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sex Hormones and Orthostatic Tolerance

NCT01153581
View directory record Official record
Conditions
Orthostatic Intolerance
Interventions
Ganirelix acetate, 17β-Oestradiol, Progesterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 25, 2026, 6:59 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids

NCT04655339
View directory record Official record
Conditions
Opioid Use
Interventions
Bilateral abdominal Lap-TAP
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

NCT03237481
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492
View directory record Official record
Conditions
Cytomegalovirus
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
44
States / cities
La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT00554827
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Vitamin B12, Folic Acid, Pralatrexate
Dietary Supplement · Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 25, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Spinal Ketorolac After Acute Opioid Exposure

NCT00693160
View directory record Official record
Conditions
Healthy
Interventions
ketorolac, placebo, remifentanil, Capsaicin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 25, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

NCT01689363
View directory record Official record
Conditions
Allergic Skin Reaction
Interventions
Hyaluronidase, Histamine, Saline
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 25, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955
View directory record Official record
Conditions
Hypertension
Interventions
Saline, QCZ484
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
64
States / cities
Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614
View directory record Official record
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Local Anesthesia for Facial Fractures

NCT06429501
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine/Epinephrine, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

NCT00996437
View directory record Official record
Conditions
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab, Saline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 25, 2026, 6:59 PM EDT
Terminated Phase 4 Interventional Results available

Exparel vs. Standard Bupivicaine for Abdominoplasty

NCT01853176
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

NCT06485258
View directory record Official record
Conditions
Rotavirus Infections
Interventions
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo
Biological · Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

TNF-α Treatment of Blast-Induced Tinnitus

NCT04066348
View directory record Official record
Conditions
Tinnitus, Noise Induced
Interventions
Etanercept, Saline
Biological · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Celebration, Florida • Coral Gables, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948
View directory record Official record
Conditions
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
Interventions
20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
27
States / cities
Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 25, 2026, 6:59 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia

NCT03582085
View directory record Official record
Conditions
Fibromyalgia
Interventions
Bacillus Calmette Guerin Vaccine, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 25, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 25, 2026, 6:59 PM EDT